Resbovis MAX
Resbovis Max Prospectus
Resbovis MAX
Pharmaceutical Form: Suspension for Injection
In cattle, it stimulates the production of antibodies against Infectious Bovine Rhinotracheitis (IBR) virus, Bovine Diarrhea (BVD) virus, Bovine Respiratory Syncytial (BRSV) virus, Bovine Parainfluenza 3 (PI 3) virus, Pasteurella multocida and Mannheimia haemolytica type A1 antigens, reducing infections and lesions caused by these agents.
Cattle
COMPOSITION:
The content of each dose of vaccine (5 ml) is as follows:
| Active ingredient | Quantity |
| Inactivated Bovine herpesvirus Type-1 (BoHV-1) antigen | ≥ 4 log2 VNT* |
| Inactivated Bovine respiratory syncytial virus (BRSV) antigen | ≥ 4 log2 VNT* |
| Inactivated Bovine parainfluenza virus-3 (BPIV-3) antigen | ≥ 6 log2 VNT* |
| Inactivated Bovine viral diarrhea (CP-BVDV) antigen | ≥ 6 log2 VNT* |
| Inactivated Bovine viral diarrhea (NCP-BVDV) antigen | ≥ 6 log2 FAVN** |
| Inactive Pasteurella multocida antigen | ≥ 1/40 ELISA seropositive *** |
| Inactive Mannheimia haemolytica A1 antigen and leukotoxin | ≥ 1/40 ELISA seropositive *** |
| Excipients | |
| Aluminum hydroxide gel (Al+3) | 1.5 mg/ml |
| Saponin | 0.3 mg/ml |
| Formaldehyde solution (37%) | 0.004 ml/ml |
*VNT (log2) titer in rabbits vaccinated with 1/2 dose
**Titer of FAVN (log2) in rabbits vaccinated with 1/2 dose
***ELISA titer in rabbits vaccinated with 1/2 dose
RESBOVİS-MAX is an inactivated vaccine against Infectious Bovine Rhinotracheitis (IBR) virus, Bovine Diarrhea (BVD) virus, Bovine Respiratory Syncytial (BRSV) virus, Bovine Parainfluenza 3 (PI 3) virus, Pasteurella multocida and Mannheimia haemolytica type A1 in cattle. Immunity begins to develop within 3 weeks in vaccinated animals, and immunity occurs by creating a complete immune response 2 weeks after the second vaccination in animals vaccinated for the first time. Active immunity persists for 6 months. The resulting active immunity reduces infections and lesions caused by these factors.
It is administered to all cattle from the age of 2 months in the amount of 5 ml subcutaneously (SC) or intramuscularly (IM) to the middle part of the lateral face of the neck or to the immobile area behind the shoulder. Animals vaccinated for the first time are given a second administration after 3 weeks. It is recommended to administer as a single dose every 6 months.
Suspension for injection: It should be stored at 2-8ºC and in the dark. Do not freeze.
Shelf life is 24 months.
Opened bottles should be used within 6-8 hours.
The vaccine is packaged in 5 ml Type I amber glass bottles, 25 ml, 50 ml and 100 ml Type II amber glass bottles or 25 ml, 50 ml, 100 ml and 250 ml white polypropylene plastic bottles. Glass and plastic bottles are labelled with a bromobutyl stopper and sealed with an aluminium cap.
5 ml bottles are offered to the market in 10×5 ml plastic tray or cardboard boxes, 25 ml, 50 ml, 100 ml and 250 ml bottles are offered to the market in styrofoam with or without individual boxes. Not all packaging formats may be available to the market at the same time.